Incorporating historical information to improve phase I clinical trials
- 1 April 2021
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 20 (6) , 1017-1034
Abstract
Incorporating historical data has a great potential to improve the efficiency of phase I clinical trials and to accelerate drug development. For model‐based designs, such as the continuous reassessment method (CRM), this can be conveniently carried out by specifying a “skeleton,” that is, the prior estimate of dose limiting toxicity (DLT) probability at each dose. In contrast, little work has been done to incorporate historical data into model‐assisted designs, such as the Bayesian optimal interval (BOIN), Keyboard, and modified toxicity probability interval (mTPI) designs. This has led to the misconception that model‐assisted designs cannot incorporate prior information. In this paper, we propose a unified framework that allows for incorporating historical data into model‐assisted designs. The proposed approach uses the well‐established “skeleton” approach, combined with the concept of prior effective sample size, thus it is easy to understand and use. More importantly, our approach maintains the hallmark of model‐assisted designs: simplicity—the dose escalation/de‐escalation rule can be tabulated prior to the trial conduct. Extensive simulation studies show that the proposed method can effectively incorporate prior information to improve the operating characteristics of model‐assisted designs, similarly to model‐based designs.Keywords
All Related Versions
Funding Information
- National Cancer Institute (P50CA127001, P50CA221707, P50CA098258, CA016672, CA221703)
- Cancer Prevention and Research Institute of Texas (RP160668, RP150519)
This publication has 23 references indexed in Scilit:
- Bridging continual reassessment method for phase I clinical trials in different ethnic populationsStatistics in Medicine, 2015
- Bayesian optimal interval designs for phase I clinical trialsJournal of the Royal Statistical Society Series C: Applied Statistics, 2014
- Robust meta‐analytic‐predictive priors in clinical trials with historical control informationBiometrics, 2014
- Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets WestStatistics in Medicine, 2011
- An approach to meta‐analysis of dose‐finding studiesStatistics in Medicine, 2011
- A modified toxicity probability interval method for dose-finding trialsClinical Trials, 2010
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical TrialsJournal of the American Statistical Association, 2009
- Determining the Effective Sample Size of a Parametric PriorBiometrics, 2008
- Critical aspects of the Bayesian approach to phase I cancer trialsStatistics in Medicine, 2008
- Power prior distributions for regression modelsStatistical Science, 2000